The results of the CCK8 assay and flow cytometry indicated that ANXA2 knockdown reverses the effect of XAB2-induced oxaliplatin resistance in CRC cells, resulting in lower IC50 values and higher apoptotic rates (Fig. 6E-F). This evidence concerns the gene ANXA2 and colorectal carcinoma.